Drug intelligence / Profile preview

Navical

Development stage: Unknown
Lead developer: Navil Laboratories
Modality: Small Molecules
Administration: Oral

Overview

Navical is an oral nutraceutical brand developed and marketed by Navil Laboratories. Its primary formulation, Navical Tablet, is a combination of calcium citrate maleate, cholecalciferol (vitamin D3), magnesium, zinc, pyridoxine (vitamin B6), folic acid, and methylcobalamin. It is also available as Navical D3, a single-ingredient cholecalciferol sachet. Navical is used as a dietary supplement to manage and prevent calcium and vitamin D3 deficiencies, support bone density, and treat bone-related disorders such as osteoporosis. The inclusion of essential B vitamins (B6, B9, B12) and minerals (magnesium, zinc) further supports neurological health, red blood cell formation, and overall metabolic functioning.

Brand names: Navical
Other names: Navical Tablet

Targets

CaSR (Extracellular calcium-sensing receptor)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Navical.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navical.